Clinical Trial Update: Phase 1 Study of ACE-083 in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 study of ACE-083 in healthy subjects has completed with results posted in 2019, focusing on musculoskeletal indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Musculoskeletal Diseases

Drugs mentioned

• ACE-083

Snippet

Sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Conditions: Musculoskeletal Diseases | Phase 1 | Status: COMPLETED | Results posted: 2019-07-08